Unicycive Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Unicycive Therapeutics, Inc. filed a Form 8-K regarding a material financing announced on March 13, 2024, with the report signed March 14, 2024. The company is a clinical-stage biotechnology company. This filing does not provide an operating-period financial update.
Financing and key financial metrics
- The company agreed to sell 50,000 shares of Series B-1 Convertible Preferred Stock at $1,000 per share for gross proceeds of $50 million.
- Placement agents Leerink Partners and Piper Sandler & Co. will receive a cash fee equal to 7% of gross proceeds, or approximately $3.5 million, plus reimbursement of certain expenses. Net proceeds were not specified.
- Proceeds are intended to support clinical development activities and general working capital.
- The initial conversion price is $1.00 per common share, subject to adjustment. Conversion is generally subject to stockholder approval of common-stock issuance exceeding the Nasdaq 19.99% threshold.
- The preferred stock accrues dividends at 8% annually, compounded annually, with the rate increasing to 14% if the required stockholder approval is not obtained at the first stockholder meeting following issuance. Dividends are payable monthly.
- The preferred stock has voting rights on an as-converted basis, subject to a cap before stockholder approval, and has a liquidation preference generally equal to the greater of 1.0 times the original purchase price plus accrued dividends or the as-converted value.
- The filing provides no revenue, profit, cash-flow, margin, debt, cash-balance, or liquidity figures.
Material changes, outlook, and risks
- Closing was expected on or about March 18, 2024, subject to customary conditions; the filing does not confirm the actual closing.
- Following stockholder approval, Series B-1 shares are scheduled to automatically convert on the tenth trading day after announcement of approval. Series B-2 shares may be convertible at the holder’s option.
- The company agreed to file a Form S-3 resale registration statement as soon as practicable after stockholder approval and no later than 15 days thereafter, with specified efforts toward effectiveness within 30 days, or 90 days if reviewed by SEC staff.
- The securities are unregistered, were offered to accredited investors under private-placement exemptions, and have no established trading market. They may not be resold absent registration or an applicable exemption.
- The transaction may result in substantial future dilution of existing common stockholders upon conversion and creates a preferred dividend and liquidation-priority obligation.
- If stockholder approval is delayed or not obtained, the preferred dividend rate may increase to 14%, and conversion limitations may remain in effect.
- The filing does not provide specific clinical-development milestones, revenue guidance, cash runway, or other quantitative forward guidance.
Most important facts to verify
- Whether the financing closed and the actual net proceeds received after placement-agent fees and expenses.
- The number of common shares outstanding and the potential dilution at the $1.00 initial conversion price, including accrued dividends and adjustment provisions.
- The timing and outcome of the required stockholder approval.
- Whether the Form S-3 resale registration statement was filed and declared effective within the stated targets.
- The company’s subsequent cash balance, liquidity runway, clinical spending plans, and any obligations associated with the preferred stock.
- The complete Certificate of Designation and Securities Purchase Agreement, which govern the definitive rights and limitations.